Skip to main content

Table 4 Association of p16 overexpression with various clinical & pathological parameters

From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer

  n (%) P-Value
Positive (n = 98) Negative (n = 34) Focal Positive (n = 5) Total (n = 137)
Age groups
  ≤ 30 years 3(3.1) 0(0) 0(0) 3(2.2) 0.460
 31–50 years 59(60.2) 16(47.1) 3(60) 78(56.9)
  > 50 years 36(36.7) 18(52.9) 2(40) 56(40.9)
Tumor stage/tumor size
 T1(≤2 cm) 16(16.3) 7(20.6) 1(20) 24(17.5) 0.964
 T2(2.1–5.0 cm) 51(52) 17(50) 3(60) 71(51.8)
 T3(> 5.0 cm) 31(31.6) 10(29.4) 1(20) 42(30.7)
ki67 index groups
  ≤ 15% 10(10.2) 5(14.7) 2(40) 17(12.4) 0.345
 16–24% 5(5.1) 3(8.8) 0(0) 8(5.8)
 25–44% 29(29.6) 11(32.4) 2(40) 42(30.7)
  > 44% 54(55.1) 15(44.1) 1(20) 70(51.1)
Nodal Status
 Positive 42(42.9) 15(44.1) 2(40) 59(43.1) 1.000
 Negative 56(57.1) 19(55.9) 3(60) 78(56.9)
Nodal Stage
 No 58(59.2) 19(55.9) 3(60) 80(58.4) 0.907
 N1 17(17.3) 8(23.5) 2(40) 27(19.7)
 N2 9(9.2) 3(8.8) 0(0) 12(8.8)
 N3 14(14.3) 4(11.8) 0(0) 18(13.1)
Histological Subtypes
 IDC 83(84.7) 28(82.4) 5(100) 116(84.7) 0.633
 Papillary 5(5.1) 0(0) 0(0) 5(3.6)
 Medullary 1(1) 0(0) 0(0) 1(0.7)
 metaplastic 8(8.2) 5(14.7) 0(0) 13(9.5)
 Mixed 1(1) 1(2.9) 0(0) 2(1.5)
Tumor Grade
 Grade-I 0(0) 1(2.9) 0(0) 1(0.7) 0.165
 Grade-II 11(11.2) 7(20.6) 0(0) 18(13.1)
 Grade-III 87(88.8) 26(76.5) 5(100) 118(86.1)
Lymhovascular Invasion
 Present 25(25.5) 6(17.6) 1(20) 32(23.4) 0.788
 Absent 73(74.5) 28(82.4) 4(80) 105(76.6)
Perinodal extension
 Present 19(19.4) 9(26.5) 0(0) 28(20.4) 0.425
 Absent 79(80.6) 25(73.5) 5(100) 109(79.6)
Triple Negative phenotype
 Basal 10(10.2) 3(8.8) 1(20) 14(10.2) 0.532
 Non Basal 88(89.8) 31(91.2) 4(80) 123(89.8)
  1. Chi-Square test applied
  2. P-Value≤0.05, considerd as significant
\